Cross-Border M&A: How to Manage Merger Filings in Multiple Jurisdictions

Managing merger filings across multiple jurisdictions is where competition law stops being a legal specialty and becomes deal architecture. One transaction, one set of facts — but a dozen authorities, each with its own thresholds, clocks, politics and remedy tastes. This guide sets out the playbook global deal teams actually use: footprint mapping, sequencing, FDI and subsidy overlays, cooperation dynamics between authorities, and the SPA clauses that decide who pays when regulators say no. It completes the merger-control pillar of our Competition & Antitrust hub.

Why do cross-border deals face so many parallel filings?

Because merger control is national, revenue-based and mandatory. Every jurisdiction where the parties’ groups exceed local thresholds gets its own veto over closing, regardless of where the deal is signed or the target sits. There is no global one-stop shop — the EUMR consolidates only the EU’s internal reviews.

The consequence is a coordination problem the parties must solve themselves: forty clocks that start at different times, information requests that overlap and contradict, remedy discussions in which each authority wants its market fixed without caring what others demanded. Left unmanaged, the footprint sets your timetable by its slowest member and your remedy bill by the union of all demands. Managed well, filings are sequenced so hard questions get answered once, early, and consistently everywhere — which is why the threshold analysis is the first work stream opened after the term sheet.

How do you map the filing footprint?

Build the revenue matrix first: each party’s group turnover by country, on competition-law counting rules, for the last audited year. Apply every plausible jurisdiction’s tests — turnover, deal-value, share-of-supply — and classify results into mandatory, prudential (borderline or discretionary) and clear negatives, with local counsel sign-off on the borderlines.

Then layer on the qualitative screens that pure numbers miss: Türkiye’s technology-undertaking exception; the UK’s elastic share-of-supply test; COMESA and other supranational regimes; and voluntary regimes where non-filing is legal but risky given overlap. The output is a filing decision memo — jurisdictions, deadlines, filing owners, fees and translation lead times — that becomes the master document for the regulatory work stream. Budget realism matters: filing fees alone range from Türkiye’s zero to the US’s up to $2.46 million, and translated notarised documents for some Asian and Middle-East filings take weeks to produce.

How do review timelines interact — and how do you sequence filings?

Sequence by difficulty, not convenience: open pre-notification first wherever the substantive risk is highest (typically the EU, US or UK), so the hardest authority’s concerns surface while the deal still has flexibility. File the mechanical jurisdictions in waves timed so that clearances do not expire — several regimes’ approvals lapse after six or twelve months — before the slow ones finish.

Watch three interaction effects. Remedy contagion: whatever you offer one authority becomes every other authority’s opening position, so never settle the easiest regime first with a generous package. Information symmetry: authorities compare notes (with waivers, formally; without, atmospherically) — inconsistent market narratives across filings are found out. Long-stop arithmetic: set the SPA long-stop off the pessimistic path of the slowest hard jurisdiction — Phase II plus remedies plus buffer — with automatic extensions if approvals are pending, because returning to the seller to beg for time is negotiating leverage surrendered. The mechanics of each stage are covered in the review process guide.

What is FDI screening — and how does it differ from merger control?

Foreign-investment screening reviews acquisitions for national-security and public-order risk, not competition. The tests turn on the investor’s identity and the target’s activities — defence, critical infrastructure, semiconductors, data, health — with no turnover thresholds and, often, call-in powers over tiny stakes. CFIUS in the US, the UK’s National Security and Investment Act, Germany’s AWV, France, Italy and most EU states under the EU FDI cooperation framework all run mandatory regimes for sensitive sectors.

Practically, FDI review is a second, parallel gate with its own timeline and its own politics: a deal can be unconditionally fine on competition and dead on security (or salvageable only through mitigation — proxy boards, supply commitments, divestment of the sensitive sliver). The FDI map follows the target’s activities and the buyer’s ultimate ownership, so run it alongside the antitrust footprint from day one, and treat state-linked or strategic-sector buyers as automatically multi-gate. Türkiye maintains sectoral screening (media, energy, defence) though no general FDI regime — but assume the list grows; the global trend is one-directional.

What is the EU Foreign Subsidies Regulation — the third gate?

Since October 2023, the FSR adds a genuinely new filing: acquisitions of EU businesses with turnover above €500 million trigger mandatory notification to the European Commission where the parties received combined non-EU “financial contributions” above €50 million over three years. The concept is sweeping — state contracts, tax breaks, loans and guarantees from any non-EU government count, whether or not they look like subsidies.

The FSR’s practical sting is data: multinational groups must inventory financial contributions worldwide, an exercise that takes months the first time. The Commission has already used the tool aggressively in procurement and has opened in-depth merger reviews (the first, e.tre… — Emirates Telecommunications’ PPF acquisition, cleared with commitments in 2024). For any large deal with a buyer enjoying non-EU state financing — Gulf funds, Chinese groups, state-adjacent investors — build FSR readiness into diligence now, not at filing.

How do competition authorities cooperate across borders?

Formally through cooperation agreements and the International Competition Network; practically through waivers the parties grant so authorities can exchange the parties’ confidential information. Granting waivers to the sophisticated authorities reviewing the same theories is usually wise — coordinated timing and consistent understanding beat parallel confusion, and refusing waivers signals fear.

Cooperation has teeth on remedies especially: authorities increasingly align divestiture perimeters and even share monitoring trustees. But cooperation is not convergence — Microsoft/Activision proved the same evidence can yield clearance in Brussels and prohibition in London. Treat each authority as an independent decision-maker sharing a common file: one global narrative, locally translated, never locally contradicted.

Which SPA clauses allocate antitrust risk — and how are they negotiated?

Five clauses do the work. Conditions precedent list the approvals that gate closing — buyers want every plausible one included; sellers want the list short and objective. The efforts covenant sets how hard the buyer must fight: “commercially reasonable efforts” at one pole, hell-or-high-water (accept any remedy demanded) at the other, with negotiated remedy caps — divestitures up to a revenue ceiling, specified crown-jewel exclusions — in between.

The long-stop date prices expected review length plus litigation or Phase II risk, ideally with extension mechanics tied to pending approvals. The reverse break fee — Adobe paid Figma $1 billion when their deal died under regulatory pressure in 2023 — compensates the seller for regulatory failure and disciplines buyer optimism at signing. And cooperation covenants govern who controls strategy, filings and remedy offers, with the seller typically obtaining consultation rights but the buyer keeping the pen. Price these clauses off the footprint memo, not off precedent boilerplate: a deal with a Phase II-risk EU overlap and a SAMR filing is not a 9-month deal, whatever last year’s template said.

What does a practical cross-border filing checklist look like?

Before signing: revenue matrix and threshold memo; substantive overlap assessment; FDI and FSR screens; filing budget and timeline; SPA risk allocation negotiated off the pessimistic path. At signing: regulatory work-stream kickoff, waiver strategy, document-discipline briefing for all deal staff.

During review: single global narrative document controlling every filing; sequenced submissions; weekly cross-jurisdiction status tracking against the long-stop; clean-team and gun-jumping discipline enforced until the last clearance lands. At closing: confirm every suspensory approval is in hand and unexpired, close, then diarise remedy compliance obligations — divestiture deadlines, monitoring reports, behavioural commitments — into the integration plan. The deals that fail this checklist do not usually die dramatically; they bleed out in extensions, waived leverage and remedy overpayment.

Frequently Asked Questions